1. Home /
  2. Pharmaceuticals

Pharmaceuticals

Allergan Reaches Settlement With Ohio Plaintiffs in Federal Opioid Litigation

Allergan Reaches Settlement With Ohio Plaintiffs in Federal Opioid Litigation

Allergan announces it has reached a settlement with two plaintiffs in Ohio in the multi-district federal litigation over opioids.

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

Rova-T failed to show a survival benefit for patients when compared with a placebo.

GlaxoSmithKline Could Be Close to a Major Upside Move

GlaxoSmithKline Could Be Close to a Major Upside Move

The long-term technical view of GSK is very bullish.

Lannett to Be U.S. Distributor of Posaconazole Delayed-Release Tablets

Lannett to Be U.S. Distributor of Posaconazole Delayed-Release Tablets

The company will be the exclusive U.S. distributor of fungal disease medication Posaconazole delayed-release tablets.

Purdue Pharma Reportedly Offers $10 Billion to $12 Billion for Opioid Settlements

Purdue Pharma Reportedly Offers $10 Billion to $12 Billion for Opioid Settlements

Purdue Pharma is offering to settle more than 2,000 lawsuits related to the opioid crisis, NBC reports.

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Johnson & Johnson's Fine May Be the Pin Prick That Keeps Bleeding

Johnson & Johnson's Fine May Be the Pin Prick That Keeps Bleeding

By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.

Johnson & Johnson Is in the News, but How Do the Charts Look?

Johnson & Johnson Is in the News, but How Do the Charts Look?

I am not focused on today's price movement of the stock but the pattern from the end of 2017.

J&J Ordered to Pay $572 Million in Oklahoma Opioid Case

J&J Ordered to Pay $572 Million in Oklahoma Opioid Case

J&J said it would appeal the judge's decision. The judgment was less than Wall Street was expecting. The stock rose after hours.